Is this a Prime Time To acquire Intellia Therapeutics Inc. (NTLA) stock

The price of Intellia Therapeutics Inc. (NASDAQ: NTLA) closed at $40.88 in the last session, up 1.87% from day before closing price of $40.13. In other words, the price has increased by $+0.75 from its previous closing price. On the day, 1315915 shares were traded. NTLA stock price reached its highest trading level at $41.07 during the session, while it also had its lowest trading level at $38.76.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



We take a closer look at NTLA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.60 and its Current Ratio is at 9.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on March 14, 2023, Upgraded its rating to Outperform and sets its target price to $57 from $54 previously.

On February 01, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $67.

Citigroup Upgraded its Sell to Neutral on January 24, 2023, whereas the target price for the stock was revised from $48 to $39.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 05 when Sepp-Lorenzino Laura sold 2,330 shares for $38.48 per share. The transaction valued at 89,659 led to the insider holds 17,629 shares of the business.

LEONARD JOHN M sold 6,673 shares of NTLA for $248,302 on Jan 04. The President and CEO now owns 766,825 shares after completing the transaction at $37.21 per share. On Jan 04, another insider, Lebwohl David, who serves as the EVP, Chief Medical Officer of the company, sold 2,574 shares for $37.21 each. As a result, the insider received 95,779 and left with 25,687 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 72.15 while its Price-to-Book (P/B) ratio in mrq is 2.69.

Stock Price History:

Over the past 52 weeks, NTLA has reached a high of $78.58, while it has fallen to a 52-week low of $32.44. The 50-Day Moving Average of the stock is 39.53, while the 200-Day Moving Average is calculated to be 50.07.

Shares Statistics:

According to the various share statistics, NTLA traded on average about 1.20M shares per day over the past 3-months and 1.57M shares per day over the past 10 days. A total of 81.26M shares are outstanding, with a floating share count of 75.75M. Insiders hold about 6.23% of the company’s shares, while institutions hold 80.40% stake in the company. Shares short for NTLA as of Jan 30, 2023 were 7.35M with a Short Ratio of 8.10M, compared to 6.63M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.63% and a Short% of Float of 9.75%.

Earnings Estimates

The company has 25 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$1.39 for the current quarter, with a high estimate of -$0.83 and a low estimate of -$1.7, while EPS last year was -$1.09. The consensus estimate for the next quarter is -$1.41, with high estimates of -$1.21 and low estimates of -$1.77.

Analysts are recommending an EPS of between -$5.55 and -$6.62 for the fiscal current year, implying an average EPS of -$6.14. EPS for the following year is -$5.95, with 27 analysts recommending between -$5.09 and -$7.67.

Revenue Estimates

A total of 27 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $90M, while the lowest revenue estimate was $38.5M, resulting in an average revenue estimate of $51.96M. In the same quarter a year ago, actual revenue was $33.05M, up 57.20% from the average estimate.